Literature DB >> 8375936

Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine.

J Hirata1, Y Kikuchi, T Kita, E Imaizumi, T Tode, K Ishii, K Kudoh, I Nagata.   

Abstract

The ability of 12-O-tetradecanoylphorbol-13-acetate (TPA) and D,L-buthionine-S,R-sulphoximine (BSO) to modulate cis-diamminedichloroplatinum(II) (CDDP) sensitivity was investigated in human ovarian cancer cell lines sensitive (KF) or with intrinsic resistance (KK and MH) to CDDP. The KK and MH cell lines were derived from ascites of patients with clear-cell carcinoma and serous cystadenocarcinoma of the ovary who both showed clinical resistance to CDDP. The CDDP IC50 value of KK and MH cells was about 4.6- and 10.2-fold higher than that of KF cells. PKC activities in the cytosol and membrane of KK and MH cells were also about 4- to 5-fold higher than those of KF cells. Proliferation of KF, KK and MH cells was inhibited in a dose-dependent manner by TPA. The membrane PKC activities in the KF cells were rapidly activated and down-regulated 24 hr after exposure to TPA, while those in the KK and MH cells were not down-regulated even after exposure to TPA for 24 hr, suggesting that the membrane form of PKC may be involved in the intrinsic resistance. Continuous exposure to 10 nM TPA for 5 days significantly reduced the CDDP sensitivity of KF and KK cells, while exposure to 10 nM TPA for 1 hr significantly elevated that of KK and MH cells. Interestingly, 1-hr exposure to 1 microM TPA induced CDDP-resistance in KK cells. Such changes in CDDP sensitivity by TPA seemed to be linked with those of cellular PKC activity, i.e., when the CDDP sensitivity was reduced by TPA, the cellular PKC rose.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375936     DOI: 10.1002/ijc.2910550332

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 2.  Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells.

Authors:  Y Kikuchi; T Kita; J Hirata; M Fukushima
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 3.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

4.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.

Authors:  M J Caliaro; P Vitaux; C Lafon; I Lochon; A Néhmé; A Valette; P Canal; R Bugat; S Jozan
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia.

Authors:  Shaloam R Dasari; Venkatramreddy Velma; Clement G Yedjou; Paul B Tchounwou
Journal:  Int J Cancer Res Mol Mech       Date:  2015-10-15

7.  Growth-inhibitory effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl combined with cisplatin on human ovarian cancer cells inoculated into nude mice.

Authors:  H Hiramatsu; Y Kikuchi; K Kudoh; T Kita; T Tode; I Nagata
Journal:  Jpn J Cancer Res       Date:  1997-10

8.  Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.

Authors:  Y Kikuchi; J Hirata; K Yamamoto; K Ishii; T Kita; K Kudoh; T Tode; I Nagata; K Taniguchi; M Kuwano
Journal:  Jpn J Cancer Res       Date:  1997-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.